



European Testicular Tumor Network – Work Meeting 2026

Prague, 9–11 September 2026

www.ettw.eu www.ettn.eu

Preliminary Program

Day 1: 9th September 2026, 12:00 – 18:00

1. *Welcome and Opening*
 - organizational remarks
2. *ETTN Framework*
 - platform, legal issues
 - structure
 - function
 - objectives
 - ethical values, equity and inclusiveness, ownership, and intellectual properties
 - others
3. *ETTN Current Tasks*
 - actions
 - communication
 - presentation and website
 - others
4. *ETTN Funding*
 - grants – national, international, including COST and ERDERA Call applications, others
 - fundraising
5. *Young Researchers Meeting*
 - PhD study and clinical practice
 - education and training programs, short-term scientific missions, mobility
 - research opportunities, grants, funding
 - others
6. *Patient Advocacy Group Meeting*
 - concepts, objectives, and needs
 - collaboration within national and international patient organizations and groups
 - involvement in education, prevention, clinical management, and research
 - others

Day 2: 10th September 2026, 8:00 – 15:00

7. *WG1 – Epidemiology and Etiology*

- incidence, mortality, and trends in Europe and worldwide
- national registries, European registry, and collaboration with eUROGEN, EURACAN, GLOBOCAN
- environmental factors research
- genetic dispositions – pan-European study and collaboration with TECAC
- others

8. *WG2 – Molecular Biology and Pathology*

- molecular aberrations and pathways in pathogenesis
- tumor microenvironment and immune response
- pathology classification and reference centers
- biobanking
- others

9. *WG3 – Biomarkers*

- miR and their implementation in clinical practice
- ctDNA
- further biomarkers, omics studies
- others

10. *WG4 – Imaging and Surgery*

- novel imaging techniques in diagnosis and prediction
- robotic surgery, training centers, guidelines, and collaboration with eUROGEN WS3
- others

11. *WG5 – Clinical Trials and Novel Therapies*

- identification of novel therapeutic targets, clinical studies
- novel treatment approaches studies – CLDN6, methylation-targeting drugs, and others
- international multidisciplinary team set up and scheduling
- others

12. *WG6 – Long-term Sequelae and Quality of Life*

- fertility and its preservation
- second malignancies, increased risk of cardiovascular and other diseases
- psychological issues
- others

Day 3: 11th September 2026, 8:00 – 14:00

13. *Resources and their sharing*

- material – patient samples, cell lines, experimental models
- technologies and know-how
- databases
- information handling and exchange, data sharing, and data mining
- others

14. *External collaborations*

- research platforms – MaGIC, TECAC, ERN-eUROGEN, ERN-EURACAN
- patient groups

- further stakeholders - public institutions, commercial companies – pharmaceutical, biotechnological, others

15. *Education activities and next meetings*

- care-providers in underrepresented countries training
- young researchers' and residents' education and training
- patients' and patient representatives' collaborations
- public awareness
- meetings, workshops, promotional activities, and other events planning